Market capitalization | $42.76m |
Enterprise Value | $37.26m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 18.45 |
P/S ratio (TTM) P/S ratio | 21.17 |
P/B ratio (TTM) P/B ratio | 3.81 |
Revenue growth (TTM) Revenue growth | -3.18% |
Revenue (TTM) Revenue | $2.02m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Nutriband:
1 Analyst has issued a forecast Nutriband:
Oct '24 |
+/-
%
|
||
Revenue | 2.02 2.02 |
3%
3%
|
|
Gross Profit | 0.59 0.59 |
24%
24%
|
|
EBITDA | -5.75 -5.75 |
24%
24%
|
EBIT (Operating Income) EBIT | -6.03 -6.03 |
23%
23%
|
Net Profit | -6.85 -6.85 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Nutriband, Inc. engages in the development of a portfolio of transdermal pharmaceutical products. It delivers abuse deterrent fentanyl transdermal system which provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain. It operates through the Pocono Coated Products and Active Intelligence segments. The company was founded by Gareth R. Sheridan and Serguei Melnik in 2016 and is headquartered in Orlando, FL.
Head office | United States |
CEO | Gareth Sheridan |
Founded | 2012 |
Website | www.nutriband.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.